Neha Vapiwala

Sep 5, 2024 | acsjournals.onlinelibrary.wiley.com | Jacob S. Hogan |E. John Orav |Neha Vapiwala |Miranda Lam

Corresponding Author Miranda B. Lam MD, MBA Department of Radiation Oncology, Brigham and Women’s Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts, USA Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA Correspondence Miranda B. Lam, Radiation Oncology, Dana-Farber Cancer Institute and Brigham Women’s Hospital, 75 Francis St, Boston, MA 02115, USA.

May 27, 2024 | urotoday.com | Neha Vapiwala

Read the Full Video TranscriptAlicia Morgans: Hi, I'm so excited today to be joined by Professor Neha Vapiwala, who is joining me from the University of Pennsylvania in Philadelphia, but also joined me at APCCC 2024 in Lugano, Switzerland. Thank you so much for being here with me today, Neha. Neha Vapiwala: Thank you so much for having me. Alicia Morgans: Wonderful.

Nov 14, 2023 | urotoday.com | Neha Vapiwala

Read the Full Video TranscriptAlicia Morgans: Hi, I'm so excited to be here today with Professor Neha Vapiwala of the University of Pennsylvania. Thank you so much for being here with me today. Neha Vapiwala: Thank you for having me. Alicia Morgans: Wonderful.

Oct 2, 2023 | redjournal.org | Neha Vapiwala |Kara N. Maxwell

• None Was the ATM mutation found in germline only, or germline and tumor? • None Was the somatic testing via liquid or tissue biopsy? • None What is the variant allele frequency (VAF) in tumor, and % tumor if in tissue? • None What other variants were found on testing? What was the total mutational burden? To determine how best to advise a patient on the clinical implications of this finding,we must first consider the following: